Annovis Bio ANVS 深 滬
等待開盤 09-08 09:30:00 美东时间
1.39
+0.010
+0.72%
華盛通- 最 高1.44
- 今 開1.40
- 成交量 153.29万股
- 最 低 1.375
- 昨 收 1.38
- 總市值 5922.26万
- 52周最高 5.50
- 市盈率 靜 --
- 換手率 3.60%
- 52周最低 1.32
- 委 比 -33.91%
- 總股本 4260.62万
- 歷史最高 132.00
- 量 比 0.82
- 振 幅 4.71%
- 歷史最低 1.11
- 每 手 1
- 風險率 0.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅768.26%！Ascendiant Capital维持RenovoRx(RNXT)"买入"评级，目标价上调至14.5美元
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从14美元升至14.5美元；HC Wainwright & Co.：维持Generate Biomedicines"买入"评级，目标价从25美元升至30美元
08-31 18:14
Annovis to Host Corporate Update Webinar on September 2, 2026
Annovis Bio, a Phase 3 biotech company, will host a webinar on September 2, 2026, at 4:00 p.m. EDT, led by CEO Maria Maccecchini. The event will cover recent progress, including full enrollment in their pivotal Phase 3 Alzheimer's disease trial, plans for long-term safety studies, and ongoing Parkinson's disease research. The company aims to share updates with stakeholders and maintain transparency.
08-25 12:00
Annovis Bio Q2 EPS $(0.40) Beats $(0.45) Estimate
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.45) by 11.11 percent. This is a 25 percent decrease over losses of $(0.32) per share from the same period last year.
08-14 20:10
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
Annovis Bio has achieved full enrollment in its pivotal Phase 3 Alzheimer’s disease (AD) trial with 850 patients, exceeding its original target. The company also reported progress in its Parkinson’s disease (PD) open-label extension study, which has enrolled 266 patients toward a goal of 500. Annovis will host a corporate update webinar on September 2, 2026, to discuss these developments. Additionally, the company provided financial results, incl...
08-14 12:00
美股大行评级 | 潜在涨幅215.37%！摩根士丹利上调TeraWulf(WULF)目标价至72美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持TeraWulf"超配"评级，目标价从66.5美元升至72美元；HC Wainwright & Co.：维持Vera Therapeutics"买入"评级，目标价从110美元升至125美元
07-09 12:35
Roth Capital Initiates Coverage On Annovis Bio with Buy Rating, Announces Price Target of $8
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Annovis Bio (NYSE:ANVS) with a Buy rating and announces Price Target of $8.
07-08 17:08
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
Annovis Bio announced the full enrollment of its pivotal Phase 3 trial for buntanetap in early Alzheimer's disease, recruiting 850 patients across 83 U.S. sites. The trial, designed to evaluate both symptomatic and disease-modifying effects, is expected to deliver 6-month symptomatic data in Q1 2027 and 18-month disease-modifying data in Q1 2028. Annovis plans to submit NDAs following each readout. The company highlighted the trust placed by pati...
07-07 11:00
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
Annovis Bio, a Phase 3 clinical-stage biotechnology company, announced the promotion of Cheng Fang, Ph.D., to Chief Scientific Officer. Dr. Fang, who joined the company in 2021, will lead scientific strategy and research operations for its Alzheimer's disease (AD) and Parkinson's disease (PD) programs. This promotion comes as the company advances its lead drug candidate, buntanetap, toward pivotal Phase 3 AD study data and NDA submission. Dr. Fan...
07-01 12:00
Annovis Bio Regains NYSE Listing Compliance
Annovis Bio, a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases, has regained compliance with New York Stock Exchange (NYSE) continued listing standards. The company was previously notified of non-compliance due to its market capitalization and stockholders' equity falling below $50 million. Annovis implemented corrective actions and restored compliance ahead of the 18-month deadline. The company r...
05-26 12:00
Why 8x8 Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Shares of 8x8 Inc (NASDAQ: EGHT) jumped 13.3% in pre-market trading after reporting better-than-expected Q4 results, with adjusted earnings of 11 cents per share and revenue of $185.25 million. GCL, PETZ, WOK, MEHA, HAO, TDIC, FEED, KELYA, and AMC were among the top gainers, while RUBI, AMIX, IPW, ANVS, and WGRX were among the top losers in pre-market trading.
05-20 16:31
